Patrick Hwu: The potential of personalized cancer vaccines as an effective adjuvant therapy in RCC
Patrick Hwu, President and CEO of Moffitt Cancer Center, shared a post on LinkedIn about a recent paper by David Braun et al. published in Nature:
“Personalized cancer vaccines (PCV) train the immune system to recognize mutations unique to a patient’s tumor, helping the body mount a targeted immune response.
Can this approach help prevent renal cell carcinoma (RCC) from returning after surgery?
In this study, Toni Choueiri (Dana-Farber Cancer Institute) et al. tested a PCV in patients with high-risk RCC, targeting key tumor mutations. All participants developed immune responses, and after 40 months, none of the 9 vaccinated patients had a recurrence, and all patients generated T cell immune responses against the PCV antigens, including RCC driver mutations.
These findings highlight the potential of personalized cancer vaccines as an effective adjuvant therapy in RCC.”
“A neoantigen vaccine generates antitumour immunity in renal cell carcinoma”
Authors: David Braun, Giorgia Moranzoni, Vipheaviny Chea, Catherine Wu, Derin Keskin, Patrick Ott et al.
More posts featuring Patrick Hwu.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023